Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 2 N=200 Targeted Dose Finding of Canakinumab (ACZ885) for Management of Acute Flare in Refractory or Contraindicated Gout Patients
Acute Gout
Primary: The Dose of Canakinumab for Treatment of Acute Flares in Gout Patients That Leads to the Same Efficacy as Triamcinolone Acetonide With Respect to Pain Intensity on a…
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 3 N=153 A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy II
Chronic Gout
Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
Phase 3 N=112 A Study of SEL-212 in Patients With Gout Refractory to Conventional Therapy
Chronic Gout
Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…
Phase 3 N=214 Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors
Gout
Primary: Number of Subjects With an sUA Level That is < 6.0 mg/dL — 32; 2 Number of Subjects — p=<0.0001
Phase 2 N=170 A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy
Chronic Gout
Primary: Number of Participants With Serum Uric Acid (SUA) Reduction of < 6 mg/dL for at Least 80% of the Time — 44; 40 Participants — p=0.181
Phase 3 N=607 Combining Lesinurad With Allopurinol in Inadequate Responders
Gout
Primary: Proportion of Subjects With an sUA Level That is < 6.0 mg/dL — 0.542; 0.592; 0.279 Proportion of Subjects — p=<0.0001
Phase 4 N=13 Pegloticase and Methotrexate Co-administered in Participants With Uncontrolled Gout Who Previously Failed Pegloticase Monotherapy
Uncontrolled Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 9.1 percentage of participants
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 3 N=610 Combining Lesinurad With Allopurinol in Inadequate Responders
Gout
Primary: Subjects With a Serum Urate (sUA) < 6.0 mg/dL by Month 6. — 0.554; 0.665; 0.233 Proportion of Subjects — p=<0.0001
Phase 4 N=54 A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)
Uncontrolled Gout · Chronic Gout
Primary: Percentage of Participants Who Were Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 68.0; 73.1 percentage of participants
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Phase 2 N=35 REduCing Immunogenicity to PegloticasE (RECIPE) Study
Gout Chronic
Primary: Proportion of Participants Achieving and Maintaining an sUA ≤ to 6 Milligram Per Deciliter (mg/dL) Through 12 Weeks — 19; 4; 3; 6 Participants — p=<0.01
Phase 3 N=324 Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Tophaceous Gout
Primary: Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6 — 0.566; 0.761; 0.468 Proportion of Subjects — p=0.1298
Phase 3 N=1,315 Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)
Gout
Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 59.1; 66.6; 13.0; 27.5 percentage of participants
Phase 4 N=152 Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6 — 71.0; 38.5 percentage of participants — p=< 0.0001
Phase 3 N=196 Lesinurad and Febuxostat Combination Extension Study in Gout
Gout
Primary: Percentage of Participants With an sUA Level That is < 5.0 mg/dL — 82.5; 77.8 Percentage of participants
Phase 4 N=15 Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout
Gout
Primary: Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6 — 78.6 percentage of participants
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
N/A N=188 Observational Study of the Use of Pegloticase (KRYSTEXXA®) in Refractory Chronic Gout
Refractory Chronic Gout
Primary: Number of Participants With Infusion Reactions — 42 Participants
Phase 3 N=230 Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Acute Gout
Primary: Time to First New Flare — NA; NA Days
Phase 3 N=248 PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 113 (Week 16) — 1.23; 0.35; 0.34 Gout flares
Phase 3 N=226 Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Acute Gout
Primary: Time to First New Flare: Survival Analysis During the 12 Weeks of Study — NA; NA Days
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001